igfbp6  (R&D Systems)

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: a) Dot plot representing IGFBP5 (left), IGFBP6 (centre) and IGFBP7 (right) expressions in different cell types in publicly available lung single-cell RNA sequencing datasets. Data was generated from the Curated Cancer Cell Atlas. The size of the circle dot represents the percentage of expressing cells, while the colour represents the mean log2 expression level, as indicated in the scale bar (below), b) mRNA expression (fold change) of IGFBP5, 6 and 7 in patient-derived lung normal fibroblasts (NF) and cancer-associated fibroblasts (CAF). Data are presented as mean ± SEM (n=3 biological triplicates). Statistical analysis was conducted using an unpaired t-test with Welch’s correction; exact p-values are represented in the graph, c) Immunoblots (IBs) showing IGFBP5, 6 and 7 expressions in whole cell lysates of NF and CAF. β-Actin served as the loading control. Densitometric analysis was done using Image Lab (v6.1.0), d) IBs showing secreted and cellular (corresponding serum-starved cell lysates) expression of IGFBP5, 6 and 7. β-Actin served as the loading control for serum-starved cellular lysates, while Ponceau blot served as the loading control for secretory lysates. All IBs are representative of three biological triplicates.

Article Snippet: Cells were lysed directly with RIPA buffer or Laemmli buffer and subjected to SDS PAGE and primary antibodies of α-Smooth Muscle Actin (#19245, CST, 1:1000), FAP (#66562, CST, 1:1000), S100A4 (#13018, CST, 1:1000), IGFBP5 (sc-515184, Santa Cruz, 1:1000), IGFBP6 (AF876, R&D Systems, 1:1000), IGFBP7(sc-365293, Santa Cruz 1:750), Phospho-p44/42 MAPK (Thr202/Tyr204) (#9101, CST, 1:2000), p44/42 MAPK (Thr202/Tyr204) (137F5)(#4695, CST, 1:2000), Phospho-Akt (Ser473) (#4060, CST, 1:2000), Akt (pan) (#2920, CST, 1:2000), Phospho-Insulin R(Y1162/Y1163)/IGF-1R (Y1132/Y1136) (AF2507, R&D Systems, 1:1000), IGF-I R/IGF1R (MAB391, R&D Systems, 1:1000), Phospho-Stat3 (Tyr705) (#9145, CST, 1:2000), Stat3 (#9139, CST, 1:2000), IL6 (#12153, CST, 1:1000), β-Actin (8H10D10) (#3700, CST, 1:2000), GAPDH (#2118, CST, 1:10,000).

Techniques: RNA Sequencing, Generated, Expressing, Derivative Assay, Western Blot, Control

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: a) Volcano plot representing differentially expressed genes between CAF siControl vs siIGFBP5 b) CAF siControl vs siIGFBP6 c) CAF siControl vs siIGFBP7 (n=3 biological replicates). A log2 fold change of 0.5 was set as the threshold. Selected genes for validation are marked in blue. d) Enriched pathways based on the differentially expressed genes upon IGFBP5 knockdown e) IGFBP6 knockdown f) IGFBP7 knockdown g) Heatmap comparing the published CAF subtype gene sets with CAF siControl versus siIGFBP5 h) CAF siControl versus siIGFBP6 i) CAF siControl versus siIGFBP7 (n=2 biological replicates)

Article Snippet: Cells were lysed directly with RIPA buffer or Laemmli buffer and subjected to SDS PAGE and primary antibodies of α-Smooth Muscle Actin (#19245, CST, 1:1000), FAP (#66562, CST, 1:1000), S100A4 (#13018, CST, 1:1000), IGFBP5 (sc-515184, Santa Cruz, 1:1000), IGFBP6 (AF876, R&D Systems, 1:1000), IGFBP7(sc-365293, Santa Cruz 1:750), Phospho-p44/42 MAPK (Thr202/Tyr204) (#9101, CST, 1:2000), p44/42 MAPK (Thr202/Tyr204) (137F5)(#4695, CST, 1:2000), Phospho-Akt (Ser473) (#4060, CST, 1:2000), Akt (pan) (#2920, CST, 1:2000), Phospho-Insulin R(Y1162/Y1163)/IGF-1R (Y1132/Y1136) (AF2507, R&D Systems, 1:1000), IGF-I R/IGF1R (MAB391, R&D Systems, 1:1000), Phospho-Stat3 (Tyr705) (#9145, CST, 1:2000), Stat3 (#9139, CST, 1:2000), IL6 (#12153, CST, 1:1000), β-Actin (8H10D10) (#3700, CST, 1:2000), GAPDH (#2118, CST, 1:10,000).

Techniques: Biomarker Discovery, Knockdown

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: a) Ligand activity analysis showing the list of potential ligands that can regulate differentially expressed genes upon IGFBP5 knockdown in CAF, d) IGFBP6 knockdown, g) IGFBP7 knockdown, b) Ligand-target matrix showing the regulatory potential of potential ligands with CAF siControl vs siIGFBP5, e) CAF siControl vs siIGFBP6, h) CAF siControl vs siIGFBP7, c) Western blot analysis of CAF siControl and siIGFBP5, f) CAF siControl and siIGFBP6, i) CAF siControl and siIGFBP7, after treatment with TGFβ1[10 ng/mL] and IL6 [10 ng/mL] for 48 hours. Densitometric analysis was done using Image Lab (v6.1.0). All IBs are representative of three biological triplicates.

Article Snippet: Cells were lysed directly with RIPA buffer or Laemmli buffer and subjected to SDS PAGE and primary antibodies of α-Smooth Muscle Actin (#19245, CST, 1:1000), FAP (#66562, CST, 1:1000), S100A4 (#13018, CST, 1:1000), IGFBP5 (sc-515184, Santa Cruz, 1:1000), IGFBP6 (AF876, R&D Systems, 1:1000), IGFBP7(sc-365293, Santa Cruz 1:750), Phospho-p44/42 MAPK (Thr202/Tyr204) (#9101, CST, 1:2000), p44/42 MAPK (Thr202/Tyr204) (137F5)(#4695, CST, 1:2000), Phospho-Akt (Ser473) (#4060, CST, 1:2000), Akt (pan) (#2920, CST, 1:2000), Phospho-Insulin R(Y1162/Y1163)/IGF-1R (Y1132/Y1136) (AF2507, R&D Systems, 1:1000), IGF-I R/IGF1R (MAB391, R&D Systems, 1:1000), Phospho-Stat3 (Tyr705) (#9145, CST, 1:2000), Stat3 (#9139, CST, 1:2000), IL6 (#12153, CST, 1:1000), β-Actin (8H10D10) (#3700, CST, 1:2000), GAPDH (#2118, CST, 1:10,000).

Techniques: Activity Assay, Knockdown, Western Blot

Journal: bioRxiv

Article Title: IGFBPs define distinct pro-tumorigenic CAF subtypes in lung cancer tumour-microenvironment

doi: 10.64898/2025.12.03.692056

Figure Lengend Snippet: a) Formalin-fixed paraffin-embedded NSCLC tumour sections were stained with hematoxylin and eosin, Sirius Red, antibodies against α-SMA, IGFBP5, 6 and 7. Cases 1 and 2 represent two different patients. ‘T’ indicates tumour and ‘S’ indicates stroma. The arrow indicates the expression of the respective proteins in fibroblasts; scale bar, 50 μm. b) Representative multiplex immunofluorescence staining images of IGFBP5+, IGFBP6+ and IGFBP7+ CAFs. DAPI (blue), αSMA (green), FAP (pink), PanCK (red), IGFBP5 (grey), IGFBP6 (yellow), IGFBP7 (orange) in human non-small-cell lung cancer tissue sections. Scale bars 50 μm. c) survival between high and low expression of CAF_IGFBP5 gene signatures d) CAF_IGFBP6 gene signatures e) CAF_IGFBP7 gene signatures in TCGA-LUAD datasets, pvalues were obtained from two-sided log-Rank tests.

Article Snippet: Cells were lysed directly with RIPA buffer or Laemmli buffer and subjected to SDS PAGE and primary antibodies of α-Smooth Muscle Actin (#19245, CST, 1:1000), FAP (#66562, CST, 1:1000), S100A4 (#13018, CST, 1:1000), IGFBP5 (sc-515184, Santa Cruz, 1:1000), IGFBP6 (AF876, R&D Systems, 1:1000), IGFBP7(sc-365293, Santa Cruz 1:750), Phospho-p44/42 MAPK (Thr202/Tyr204) (#9101, CST, 1:2000), p44/42 MAPK (Thr202/Tyr204) (137F5)(#4695, CST, 1:2000), Phospho-Akt (Ser473) (#4060, CST, 1:2000), Akt (pan) (#2920, CST, 1:2000), Phospho-Insulin R(Y1162/Y1163)/IGF-1R (Y1132/Y1136) (AF2507, R&D Systems, 1:1000), IGF-I R/IGF1R (MAB391, R&D Systems, 1:1000), Phospho-Stat3 (Tyr705) (#9145, CST, 1:2000), Stat3 (#9139, CST, 1:2000), IL6 (#12153, CST, 1:1000), β-Actin (8H10D10) (#3700, CST, 1:2000), GAPDH (#2118, CST, 1:10,000).

Techniques: Formalin-fixed Paraffin-Embedded, Staining, Expressing, Multiplex Assay, Immunofluorescence

Journal: EMBO Molecular Medicine

Article Title: Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer

doi: 10.1038/s44321-024-00069-3

Figure Lengend Snippet: ( A ) Western blot analysis evaluating the expression of ITGA6 and CD63 (marker of extracellular vesicles) in conditioned medium (CM) and whole cell lysates of TOV-112D PT-res cells treated with CDDP for the indicated time points. ( B ) Western blot analysis to compare ITGA6 and CD63 expression in whole lysates (LYS), CM, exosomes (EXO) and exosomes-depleted CM (DEPR). ( C ) Western blot analysis of ITGA6 and CD63 in exosomes isolated from CM of the indicated cells treated with CDDP for 3, 6, and 9 h. ( D , E ) Graphs reporting the area of ovaryspheres formed by TOV-112D parental cells primed with exosomes ( D ) or CM ( E ) of TOV-112D PT-res ITGA6WT and KO cells and then plated on a mesothelial cells monolayer (NC = Not Conditioned). In ( E ), representative phase-contrast images were also reported under the graph. Scale bars, 50 μm. In ( D ) and ( E ), data represent the median (± SD) of three independent experiments performed in triplicate in which at least 70 randomly selected cells were analyzed. Statistical significance was determined by a two-tailed, unpaired Student’s t-test (Exact p values were reported on graphs). ( F ) Western blot analysis evaluating the expression of the indicated proteins in whole cell lysates of TOV-112D PT-sen cells challenged for the indicated time points with the CM from TOV-112D PT-res ITGA6WT or ITGA6KO cells. NC = Not Conditioned. ( G ) Western blot analysis evaluating the expression of the indicated proteins in TOV-112D PT-sen cells incubated or not (NC) for the indicated times with the CM from TOV-112D PT-res WT in the presence or not of the anti-ITGA6 blocking antibody, GoH3. ( H ) Western blot analysis evaluating the expression of the indicated proteins in TOV-112D PT-sen cells incubated or not (NC) for the indicated times with the CM from TOV-112D PT-res WT cells in the presence or not of the Src inhibitor, Saracatinib. ( I ) Co-immunoprecipitation (Co-IP) analysis of ITGA6 and IGF1Rβ receptor in TOV-112D PT-res ITGA6WT or ITGA6KO cells. ( J ) Co-IP analysis of ITGA6 and IGF1Rβ receptor in TOV-112D parental cells incubated or not (NC) with the CM from TOV-112D PT-res WT in the presence or not of the anti-ITGA6 blocking antibody, GoH3. In ( H ) and ( I ), input shows the expression of the indicated proteins in the lysates used for the IP experiments; IgG represents the control IP using an unrelated antibody. ( K ) Table reporting the expression of the 7 proteins related to IGF1R pathway present in the used cytokine array. The mean fold ( n = 3 replicates) reports the ratio between the expression of each cytokine in the CM of PT-res ITGA6KO compared to that in the CM of PT-res ITGA6WT cells. Statistical significance was determined by a two-tailed, unpaired Student’s t-test (Exact p values were reported on graphs). ( L ) Western blot analysis evaluating the expression of IGFBP6 in CM and whole lysates of TOV-112D PT-res ITGA6WT or ITGA6KO cells. ( M ) Western blot analysis of the indicated proteins in cell lysates of TOV-112D PT-sen cells incubated or not (NC) for the indicated times with the CM of TOV-112D PT-res ITGA6 KO cells in presence or not of the specific anti-IGFBP6 blocking antibody. In the figure GAPDH was used as loading control. .

Article Snippet: In both functional assays, the challenging of TOV-112D PT-sen cells or mesothelial cells with CM from ITGA6 WT or KO cells, could be also in presence or absence of anti-ITGA6 blocking antibody, GoH3 (10 μg/ml) or anti-IGFBP6 blocking antibody (15 μg/ml) (AF876, R&D System) as indicated.

Techniques: Western Blot, Expressing, Marker, Isolation, Two Tailed Test, Incubation, Blocking Assay, Immunoprecipitation, Co-Immunoprecipitation Assay, Control

Journal: EMBO Molecular Medicine

Article Title: Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer

doi: 10.1038/s44321-024-00069-3

Figure Lengend Snippet: ( A ) Schematic representation of the experimental procedures used. Mesothelial cells (LPL) cells were incubated or not with CM of TOV-112D PT-res ITGA6WT or ITGA6KO cells for 16 h and then used for adhesion assays with TOV-112D PT-sen cells or for protein and mRNA expression analysis by western blot and qRT-PCR. NC = Not Conditioned. ( B ) Graph (left) and representative phase-contrast images (right) reporting the area of ovaryspheres formed by TOV-112D PT-sen cells plated on mesothelial cells monolayer primed as described in ( A ). Data represent the median (± SD) of three independent experiments performed in triplicate in which at least 70 randomly selected cells were analyzed. ( C ) Western blot analysis evaluating the expression of IGFBP6 and IGF2 in mesothelial whole cell lysates treated as described in ( A ). ( D ) Western blot analysis evaluating the expression of the indicated proteins in whole cell lysates of mesothelial cells conditioned or not (NC) for the indicated times with CM of TOV-112D PT-res ITGA6KO cells in presence or not of the specific anti-ITGA6 GoH3 Ab. In ( C ) and ( D ), Tubulin was used as loading control. ( E ) Graph reporting the mRNA expression of IGF2 and LAMA5 (LM) in mesothelial cells incubated for the indicated times as described in ( A ). NC = Not Conditioned. Data are the mean (± SD) of 3 replicates. ( F ) Clinical history of patient #1 reporting the timeline of chemotherapy treatments and ascites collections. The amount of CA125 (in blood samples) and ITGA6 (in ascites) were reported in red and blue, respectively. ( G ) Graph (top) and representative phase-contrast images (bottom) reporting the area of ovaryspheres formed by TOV-112D PT-sen cells plated on mesothelial cells monolayer conditioned or not (NC) for 16 h with ascites samples described in ( F ), in the presence of the specific anti-ITGA6 blocking antibody GoH3, as indicated. Data represent the median (± SD) of three independent experiments performed in triplicate in which at least 70 randomly selected cells were analyzed. ( H ) Schematic representation depicting the role of ITGA6 in inducing a PT-resistant phenotype (increased invasion, adhesion, and stemness) both at cell-autonomous and non-cell-autonomous levels, leading to the formation of the pre-metastatic niche. Overexpression of ITGA6 allows a better adhesion of PT-res cells to the mesothelium. ITGA6 engagement induces stabilization of Snail and inhibition of IGFBP6 expression that promote invasion and stem-like behavior. On the other side secreted ITGA6 acts on PT-sen and mesothelial cells to activate the IGF1R pathway and amplify the pro-metastatic signals. ITGA6 KO, or its inhibition with blocking antibodies, prevents the activation of pro-metastatic metastatic pathways both in PT-res cells and in recipient cells and impairs IGF1R signaling by releasing the inhibition on IGFBP6 transcription leading to its overproduction. In ( B ) and ( G ), data represent the mean (± SD) of two independent experiments performed in triplicate in which at least 10 randomly selected fields were analyzed. Scale bars, 50 μm. In the figure statistical significance was determined by a two-tailed, unpaired Student’s t-test (Exact p values were reported on graphs). .

Article Snippet: In both functional assays, the challenging of TOV-112D PT-sen cells or mesothelial cells with CM from ITGA6 WT or KO cells, could be also in presence or absence of anti-ITGA6 blocking antibody, GoH3 (10 μg/ml) or anti-IGFBP6 blocking antibody (15 μg/ml) (AF876, R&D System) as indicated.

Techniques: Incubation, Expressing, Western Blot, Quantitative RT-PCR, Control, Blocking Assay, Over Expression, Inhibition, Activation Assay, Two Tailed Test

Journal: EMBO Molecular Medicine

Article Title: Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer

doi: 10.1038/s44321-024-00069-3

Figure Lengend Snippet: ( A ) Schematic representation of the in vivo experimental procedures. NSG mice injected intraperitoneally (IP) with TOV-112D PT-res ITGA6WT ( n = 11) or ITGA6KO ( n = 11) cells, were randomly divided into two group and treated ( n = 6) or not ( n = 5) with CBDCA as indicated. Mice were sacrificed 30 days after the injection. ( B ) Graph reporting total number of tumors in mice described in ( A ), determined by macroscopic and pathological analyses (total tumor burden). ( C , D ) Radar ( C ) and Dot ( D ) plots reporting the distribution of abdominal metastasis ( C ) and the total number of organs infiltrated by cancer cells ( D ) in mice described in ( A ). In ( C ), black (WT cells) and red (ITGA6KO cells) lines indicate the number (values 0 to 5 for untreated and 0 to 6 for CBDCA-treated mice) of mice affected for each district, as indicated. Typical images of hematoxylin and eosin (H&E) staining of the showing liver metastasis in mice injected with ITGA6WT PT-res cells and treated as described in ( A ). 5X (scale bar = 200 μm) and 10X (scale bar = 50 μm) images of the same field are shown. White dashed boxes represent the magnified areas. ( E , G ) Western blot analysis evaluating the expression of ITGA6 and Snail in tumor masses ( E ) and IGFBP6 in the tumor masses ( F ) and ascites ( G ) of mice described in ( A ). Tubulin and Ponceau were used as loading controls. Mice 3 and 4 injected with ITGA6KO cells were treated with CBDCA. ( H ) Schematic representation of the in vivo experimental procedures using EOC PDX model. NSG mice injected IP with PDX OV218.3 ( n = 20), were randomly divided into four groups and treated or not ( n = 5) with the specific anti-ITGA6 blocking antibody ( n = 5), P5G10 ( n = 5), with CBDCA ( n = 5) or with the combination of both ( n = 5), according to the scheme. ( I ) Radar plots reporting the distribution of abdominal metastasis in mice injected intraperitoneally and treated as in ( H ), as determined by macroscopic and pathological analyses. Colored bold lines in each plot indicate the number (values 0 to 5) of mice affected for each district. ( J ) Typical images of H&E analyses of the omentum and lungs of mice described in ( H ). For each condition, 20X (for omentum, scale bar = 50 μm) and 40X (for lungs, scale bar = 20 μm) images are shown. Yellow dashed lanes in lung images highlighted the tumor metastasis. ( K ) Graph reporting total number of metastasis/mouse treated as indicated and determined by pathological analyses ( L ) Western Blot analysis of γH2AX in tumor cells isolated from ascites of mice described in ( H ). ( M ) Typical images of Snail (green) expression on peritoneal metastasis collected from mice described in ( H ) and evaluated by IF analyses (nuclei are in blue). White dashed lines indicate the boundary between tumor masses and the peritoneal wall. Scale bars = 20 μm. In ( B ), ( D ), and ( K ) Statistical significance was determined by a two-tailed, unpaired Student’s t-test (Exact p values were reported on graphs). Bars represent Standard Deviation. .

Article Snippet: In both functional assays, the challenging of TOV-112D PT-sen cells or mesothelial cells with CM from ITGA6 WT or KO cells, could be also in presence or absence of anti-ITGA6 blocking antibody, GoH3 (10 μg/ml) or anti-IGFBP6 blocking antibody (15 μg/ml) (AF876, R&D System) as indicated.

Techniques: In Vivo, Injection, Staining, Western Blot, Expressing, Blocking Assay, Isolation, Two Tailed Test, Standard Deviation

Journal: EMBO Molecular Medicine

Article Title: Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer

doi: 10.1038/s44321-024-00069-3

Figure Lengend Snippet: ( A , B ) Graph reporting the volume of ascitic fluids ( A ) and of explanted macroscopically identified tumors of NSG mice injected intraperitoneally with PT-res ITGA6 WT ( n = 11) and KO cells ( n = 11) and treated ( n = 6) or not ( n = 5) with CBDCA 30 mg/kg 3 times per week for 2 weeks. ( C ) Typical images of mice described in ( A ) and ( B ). Red arrows indicated the presence of macroscopically visible tumors. ( D ) Clinical history reporting the timeline of surgery, chemotherapy treatments (in green) and ascites collection of EOC patient who donate her ascites to establish PDX OV218.3 (see Methods section). ( E , F ) Graph reporting the volume of ascitic fluids ( E ) and number of tumor spheroids ( F ) in NSG mice ( n = 5/group of treatment) injected with PDX OV218.3 and treated or not with the specific anti-ITGA6 blocking antibody P5G10, with CBDCA or with the combination of both according to the scheme reported in Fig. . ( G ) IGFBP6 mRNA expression in tumor cells in ascites of mice described in ( E , F ). mRNA expression was analyzed in triplicate and normalized to actin housekeeping gene expression. The mean (±SD) expression for each mouse is reported in the graph. ( H ) IF analyses evaluating the expression of pIGF1Rβ (green) and ITGA6 (red) on peritoneal metastases collected from mice treated as indicated (nuclei are in blue). White dashed lines indicate the boundary between tumor masses and the peritoneal wall. Yellow dashed boxes represent the areas magnified in the zoomed images, on the right. Scale bars = 20 μm. In the figure, statistical significance was determined by a two-tailed, unpaired Student’s t-test (Exact p values were reported on graphs). Bars represent Standard Deviation.

Article Snippet: In both functional assays, the challenging of TOV-112D PT-sen cells or mesothelial cells with CM from ITGA6 WT or KO cells, could be also in presence or absence of anti-ITGA6 blocking antibody, GoH3 (10 μg/ml) or anti-IGFBP6 blocking antibody (15 μg/ml) (AF876, R&D System) as indicated.

Techniques: Injection, Blocking Assay, Expressing, Gene Expression, Two Tailed Test, Standard Deviation

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: IGFBP6 was detected by immunostaining in primary NPC tissues (magnification ×200). Left:, IGFBP6 positive staining; Middle: IGFBP6 negative staining; Right: isotype control staining ( A ) IGFBP6 mRNA was measured in five NPC cell lines (CNE2, CNE1, SUNE1, HK1 and HONE1) via RT-PCR, with GAPDH as an internal control ( B ) Data are representative of three separate experiments. Western blotting of whole-cell lysates to detect IGFBP6 ( C ) IGFBP6 levels in CM from NPC cells as measured by ELISA ( D ) Data are representative of two separate experiments. All data represent means ± SD from triplicates.

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: Immunostaining, Staining, Negative Staining, Control, Reverse Transcription Polymerase Chain Reaction, Western Blot, Enzyme-linked Immunosorbent Assay

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: Correlation of IGFBP6 expression with clinical characteristics in patients with NPC

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: Expressing

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: Multivariate Cox regression analysis for survival prognostic factors in advanced nasopharyngeal carcinoma

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: Expressing

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: CNE2 (upper panel) and HK1 (lower panel) cell proliferation as measured by MTS assay ( A ) Data represent means ± SD from six wells. * P < 0.05 compared to controls (IGFBP6 0 ng/ml). In transwell assays (upper panel), exogenous IGFBP6 inhibited CNE2 and HK1 cell invasion compared to controls ( B ) Invasive Index (%) was calculated (lower panel) according to the manufacturer's instructions. Columns, means of triplicate assays; bars, SE. ** P < 0.01 compared to controls.

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: MTS Assay

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: CNE2 cells were stably transfected with IGFBP6-shRNA. Real-time RT-PCR confirmed knockdown efficiency ( A ) Bars, ± SE. Data are representative of three separate experiments. Western blotting confirmed IGFBP6 knockdown ( B ) IGFBP6 knockdown induced tumor cell proliferation compared to controls ( C ) Representative wound-healing assay images ( D ) IGFBP6 knockdown increased tumor cell migration ( E ) Data represent means ± SD. * P < 0.05 compared to controls. Western blotting revealed GSK3β/β-catenin/cylin D1 pathway activation as a result of IGFBP6 knockdown ( F ).

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: Stable Transfection, Transfection, shRNA, Quantitative RT-PCR, Knockdown, Western Blot, Wound Healing Assay, Migration, Activation Assay

Journal: Oncotarget

Article Title: IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker

doi: 10.18632/oncotarget.11886

Figure Lengend Snippet: Silencing IGFBP6 expression in CNE2 cells promotes tumor metastasis in a mouse model

Article Snippet: Recombinant human IGFBP6 (rhIGFBP6) and the anti-human IGFBP6 monoclonal antibody were purchased from R&D Systems (Minneapolis, MN).

Techniques: Expressing